PL2588457T3 - Pochodne pirazolochinolinowe jako inhibitory dna-pk - Google Patents
Pochodne pirazolochinolinowe jako inhibitory dna-pkInfo
- Publication number
- PL2588457T3 PL2588457T3 PL11729377T PL11729377T PL2588457T3 PL 2588457 T3 PL2588457 T3 PL 2588457T3 PL 11729377 T PL11729377 T PL 11729377T PL 11729377 T PL11729377 T PL 11729377T PL 2588457 T3 PL2588457 T3 PL 2588457T3
- Authority
- PL
- Poland
- Prior art keywords
- inhibitors
- dna
- pyrazoloquinoline derivatives
- pyrazoloquinoline
- derivatives
- Prior art date
Links
- UXYHZIYEDDINQH-UHFFFAOYSA-N C1=CNC2=C3C=NN=C3C=CC2=C1 Chemical class C1=CNC2=C3C=NN=C3C=CC2=C1 UXYHZIYEDDINQH-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010025786A DE102010025786A1 (de) | 2010-07-01 | 2010-07-01 | Pyrazolochinoline |
| PCT/EP2011/003127 WO2012000632A1 (de) | 2010-07-01 | 2011-06-24 | Pyrazolochinoline |
| EP11729377.9A EP2588457B1 (de) | 2010-07-01 | 2011-06-24 | Pyrazolochinolinderivate als dna-pk-inhibitoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2588457T3 true PL2588457T3 (pl) | 2015-04-30 |
Family
ID=44627920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11729377T PL2588457T3 (pl) | 2010-07-01 | 2011-06-24 | Pochodne pirazolochinolinowe jako inhibitory dna-pk |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8802712B2 (pl) |
| EP (1) | EP2588457B1 (pl) |
| JP (1) | JP5411393B2 (pl) |
| KR (1) | KR101921764B1 (pl) |
| CN (1) | CN103080092B (pl) |
| AU (1) | AU2011273968B2 (pl) |
| BR (1) | BR112012033425A2 (pl) |
| CA (1) | CA2804069C (pl) |
| CY (1) | CY1115974T1 (pl) |
| DE (1) | DE102010025786A1 (pl) |
| DK (1) | DK2588457T3 (pl) |
| EA (1) | EA022430B1 (pl) |
| ES (1) | ES2528447T3 (pl) |
| HR (1) | HRP20150030T1 (pl) |
| IL (1) | IL223872A (pl) |
| MX (1) | MX2012014638A (pl) |
| PL (1) | PL2588457T3 (pl) |
| PT (1) | PT2588457E (pl) |
| RS (1) | RS53831B1 (pl) |
| SG (1) | SG186870A1 (pl) |
| SI (1) | SI2588457T1 (pl) |
| WO (1) | WO2012000632A1 (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014KN02601A (pl) | 2012-04-24 | 2015-05-08 | Vertex Pharma | |
| US9464085B2 (en) * | 2012-08-17 | 2016-10-11 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
| SMT202100687T1 (it) | 2013-03-12 | 2022-01-10 | Vertex Pharma | Inibitori della dna-pk |
| ES2705342T3 (es) | 2013-10-17 | 2019-03-22 | Vertex Pharma | Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK |
| EP3518931A4 (en) | 2016-09-27 | 2020-05-13 | Vertex Pharmaceuticals Incorporated | METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS |
| CA3049608A1 (en) * | 2017-01-09 | 2018-07-12 | Suixiong Cai | Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof |
| CN108295070B (zh) * | 2018-01-08 | 2020-08-11 | 华中农业大学 | 一种喹啉衍生物在制备肿瘤抑制药物中的用途 |
| US12534465B2 (en) | 2019-06-10 | 2026-01-27 | Sutro Biopharma, Inc. | 5H-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof |
| EP3980080A1 (en) | 2019-06-10 | 2022-04-13 | Sutro Biopharma, Inc. | Immunomodulator antibody drug conjugates and uses thereof |
| US20220259202A1 (en) * | 2019-06-17 | 2022-08-18 | Sutro Biopharma, Inc. | 1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis |
| EP4015506A4 (en) * | 2019-09-25 | 2023-08-30 | Korea Institute of Radiological & Medical Sciences | COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING A DERIVATIVE BASED ON TRIFLUOROMETHYLPHENYL PYRAZOLE AS ACTIVE PRINCIPLE |
| KR102663365B1 (ko) * | 2019-09-25 | 2024-05-08 | 한국원자력의학원 | 신규 트리플루오로메틸페닐피라졸 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0556310B1 (en) | 1990-11-06 | 1995-07-05 | Pfizer Inc. | Quinazolines derivatives for enhancing antitumor activity |
| EP1187633A4 (en) | 1999-04-08 | 2005-05-11 | Arch Dev Corp | USE OF ANTI-VEGF ANTIBODIES TO ENHANCE RADIATION IN ANTICANCER THERAPY |
| GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| CA2532800C (en) * | 2003-07-23 | 2013-06-18 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| EP1910365A4 (en) * | 2005-07-22 | 2009-07-15 | Merck & Co Inc | INHIBITORS OF CHECKPOINT KINASES |
| WO2009155527A2 (en) | 2008-06-19 | 2009-12-23 | Progenics Pharmaceuticals, Inc. | Phosphatidylinositol 3 kinase inhibitors |
| EP2324029A4 (en) * | 2008-09-10 | 2011-09-14 | Kalypsys Inc | HETEROCYCLIC HEMMER OF HISTAMINE RECEPTORS FOR DISEASE TREATMENT |
-
2010
- 2010-07-01 DE DE102010025786A patent/DE102010025786A1/de not_active Withdrawn
-
2011
- 2011-06-24 MX MX2012014638A patent/MX2012014638A/es active IP Right Grant
- 2011-06-24 BR BR112012033425-5A patent/BR112012033425A2/pt not_active Application Discontinuation
- 2011-06-24 PL PL11729377T patent/PL2588457T3/pl unknown
- 2011-06-24 CN CN201180042341.XA patent/CN103080092B/zh active Active
- 2011-06-24 CA CA2804069A patent/CA2804069C/en active Active
- 2011-06-24 RS RS20150083A patent/RS53831B1/sr unknown
- 2011-06-24 DK DK11729377.9T patent/DK2588457T3/en active
- 2011-06-24 PT PT117293779T patent/PT2588457E/pt unknown
- 2011-06-24 US US13/807,954 patent/US8802712B2/en active Active
- 2011-06-24 EA EA201300073A patent/EA022430B1/ru not_active IP Right Cessation
- 2011-06-24 KR KR1020137002056A patent/KR101921764B1/ko active Active
- 2011-06-24 HR HRP20150030AT patent/HRP20150030T1/hr unknown
- 2011-06-24 AU AU2011273968A patent/AU2011273968B2/en active Active
- 2011-06-24 EP EP11729377.9A patent/EP2588457B1/de active Active
- 2011-06-24 JP JP2013517070A patent/JP5411393B2/ja active Active
- 2011-06-24 SG SG2012096517A patent/SG186870A1/en unknown
- 2011-06-24 SI SI201130382T patent/SI2588457T1/sl unknown
- 2011-06-24 ES ES11729377.9T patent/ES2528447T3/es active Active
- 2011-06-24 WO PCT/EP2011/003127 patent/WO2012000632A1/de not_active Ceased
-
2012
- 2012-12-25 IL IL223872A patent/IL223872A/en active IP Right Grant
-
2015
- 2015-01-30 CY CY20151100095T patent/CY1115974T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012014638A (es) | 2013-02-07 |
| US8802712B2 (en) | 2014-08-12 |
| JP5411393B2 (ja) | 2014-02-12 |
| SG186870A1 (en) | 2013-02-28 |
| EA201300073A1 (ru) | 2013-11-29 |
| KR20130041139A (ko) | 2013-04-24 |
| EA022430B1 (ru) | 2015-12-30 |
| CY1115974T1 (el) | 2017-01-25 |
| RS53831B1 (sr) | 2015-06-30 |
| WO2012000632A1 (de) | 2012-01-05 |
| BR112012033425A2 (pt) | 2020-08-18 |
| CN103080092B (zh) | 2014-12-17 |
| CA2804069C (en) | 2018-06-12 |
| HK1184782A1 (en) | 2014-01-30 |
| AU2011273968B2 (en) | 2014-11-20 |
| EP2588457A1 (de) | 2013-05-08 |
| EP2588457B1 (de) | 2014-11-05 |
| HRP20150030T1 (hr) | 2015-03-13 |
| KR101921764B1 (ko) | 2018-11-23 |
| JP2013531663A (ja) | 2013-08-08 |
| CN103080092A (zh) | 2013-05-01 |
| AU2011273968A1 (en) | 2013-02-14 |
| IL223872A (en) | 2016-02-29 |
| DE102010025786A1 (de) | 2012-01-05 |
| CA2804069A1 (en) | 2012-01-05 |
| ES2528447T3 (es) | 2015-02-10 |
| DK2588457T3 (en) | 2015-01-12 |
| US20130150359A1 (en) | 2013-06-13 |
| PT2588457E (pt) | 2015-02-05 |
| SI2588457T1 (sl) | 2015-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2769980T3 (pl) | Pochodna pirazolochinoliny jako inhibitory PDE9 | |
| IL221823A (en) | Pipridine-4-Il-Aztidine Derivatives as Jack 1 Suppressors | |
| IL252108A0 (en) | cdk inhibitors | |
| EP2552208A4 (en) | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | |
| ZA201407554B (en) | Dna-pk inhibitors | |
| EP2552214A4 (en) | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | |
| EP2552211A4 (en) | INDAZOLYL-PYRIMIDINE AS KINASEHEMMER | |
| EP2576552A4 (en) | BENZOQUINOLONE INHIBITORS OF VMAT2 | |
| PL2588457T3 (pl) | Pochodne pirazolochinolinowe jako inhibitory dna-pk | |
| ZA201203326B (en) | Imidazopyridine derivatives as jak inhibitors | |
| GB201004179D0 (en) | Enzyme inhibitors | |
| AP3529A (en) | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors | |
| GB201004178D0 (en) | Enzyme inhibitors | |
| GB201009731D0 (en) | Kinase inhibitors | |
| GB201016880D0 (en) | Phosphodiesterase inhibitors | |
| ZA201206456B (en) | Uses of dgati inhibitors | |
| SG11201503977PA (en) | Azaindole derivatives as jak3 inhibitors | |
| ZA201404533B (en) | Quinoline derivatives as pde10a enzyme inhibitors | |
| AU2019222801A1 (en) | Glucosylceramide synthase inhibitors | |
| AU2018200675A1 (en) | Glucosylceramide synthase inhibitors | |
| GB201018597D0 (en) | Inhibitors | |
| GB201006605D0 (en) | Novel inhibitors | |
| GB201003936D0 (en) | Novel inhibitors | |
| GB201003502D0 (en) | Novel inhibitors | |
| ZA201308697B (en) | Hydroxymethylaryl-substituted pyprolotriazines as alk1 inhibitors |